Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Adeno-associated virus (AAV)-mediated gene therapy is under investigation as a therapeutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ. METHODS: We report durable efficacy, long-term safety, and clinical and biologic results in 15 adults with severe hemophilia A (factor VIII level, ≤1 IU per deciliter) who had received a single infusion of AAV5-hFVIII-SQ at various dose levels. We evaluated the factor VIII level, annualized rate of bleeding events, use of factor VIII, safety, expression kinetics, and biologic markers of AAV transduction for up to 3 years. RESULTS: vg per kilogram) had a median factor VIII expression of 13 IU per deciliter; the median annualized rate of bleeding events was 0, and the median use of factor VIII was reduced from 155.5 infusions to 0.5 infusions per year. Bleeding in target joints resolved in five of six participants. The factor VIII pharmacodynamic profiles reflected cellular turnover in the blood and molecular events leading to episomal DNA stabilization for persistent expression, findings that are consistent with previous observations in two model systems. Transgene-derived human factor VIII (hFVIII) protein activity mirrored native hFVIII in hemostatic ability. No inhibitor development, thromboses, deaths, or persistent changes in liver-function tests were observed. CONCLUSIONS: vg per kilogram of the gene therapy. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795; EudraCT number, 2014-003880-38.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 5 subjects across 3 trials experienced self-limited, vector-infusion reactions at doses of 2 × 1012−6 × 1013 vg/kg, characterized by fever, myalgias, and/or hypotension, which appear consistent with an innate immune response.141,150,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [105]
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Definitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Self-citationAntioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 673
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Research works printed but not linked: 2
- Torres R, Patton K, Holcomb J, Zoog S, Russell C, Vettermann C. Characterization of AAV5-FVIII-SQ vector DNA in human blood by real-time and Droplet Digital PCR. Mol Ther 2019;27(4):Suppl 1:436-436.
- Fong S, Handyside B, Sihn C-R, et al. The potential for induction of ER stress response by an AAV5-based construct of B-domain deleted FVIII is dependent on the strength of the hepatic specific promoter. Mol Ther 2018;26(5):Suppl 1:375-376.
Cited by
Items 301–400 of 453
Gene Therapy for Hemophilia: Are Expectations Matching Reality?
Pierce, G. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.019 · Cited by 7
Self-citationKwon, H.-J., Qing, K., Ponnazhagan, S., Wang, X.-S., Markusic, D. M., Gupte, S., Boye, S. E., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.018 · Cited by 6
Challenges and Future Directions for Next-Generation Drug Delivery Systems
Sarma, L., Singh, S., Anjali, & Dutta, D. (2025) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-4554-3_25 · Cited by 10
Adeno-associated virus gene therapy for hemophilia: an update meta-analysis and systematic review
Yang, W., Wang, A., & Liu, B. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1580264 · Cited by 6
Advances in Gene Therapy Clinical Trials for Hemophilia Care
Rana, A. J., Hussain, M. S., Jakhmola, V., & Gupta, G. (2025) · Current Gene Therapy · doi:10.2174/0115665232413510250904105956 · Cited by 6
Kumar, V., Kalishwaralal, K., Chauhan, C., Singh, G., Barnwal, R. P., & Sharma, S. K. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1678325 · Cited by 7
Handyside, B., Zhang, L., Yates, B., Xie, L. Y., Ismail, A. M., Murphy, R., Baridon, B., Su, C., Bouwman, T., Mangini, L., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.065 · Cited by 7
Chen, J.-H., Zhan, L.-J., Lv, C.-M., Teng, J.-B., & Cao, C. (2025) · Current Medical Science · doi:10.1007/s11596-025-00084-6 · Cited by 8
Zou, P. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15597 · Cited by 7
Clogging up the pipeline: factor VIII aggregates
Sabatino, D. E. (2020) · Blood · doi:10.1182/blood.2020005450 · Cited by 6
Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives
Lara-Navarro, I. J., & Jaloma‐Cruz, A. R. (2022) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.256.197 · Cited by 7
Sarangi, P., Senthilkumar, M. B., Amit, S., Kumar, N., & Jayandharan, G. R. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18460 · Cited by 7
Russell, C. B., Vettermann, C., Agarwal, S., Witt, E., Clark, W. T., Arens, J., Fronza, R., Obrochta, K. M., Kasprzyk, T., Robinson, T. M., et al. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.236 · Cited by 5
Self-citationLiu, W., Pei, X., Yu, T., Xu, B., Dai, X., Xue, F., Chen, L., Wang, X., Wang, Y., Chen, Y., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02599-3 · Cited by 9
Oldenburg, J., Chambost, H., Liu, H., Hawes, C. R., You, X., Yang, X., Newman, V., Robinson, T. M., Hatswell, A. J., Hinds, D. R., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02834-9 · Cited by 5
Transforming Hemophilia Management: Lessons from Gene Therapy Clinical Trials
Hussain, M. S., Maqbool, M., Arab, M. M., Rana, A. J., Ashique, S., Khan, Y., Jakhmola, V., & Gupta, G. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01464-y · Cited by 6
Santos, S., Robinson, T. M., & Trueman, D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03368-4 · Cited by 5
Manson, M. A., Zhang, F., Novokhodko, A., Chen, C., Parker, M. H., Loeb, K. R., Kajimoto, M., Campbell, C., Storb, R. F., & Miao, C. H. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006016 · Cited by 5
Proof-of-concept study for liver-directed miQURE technology in a dyslipidemic mouse model
Zancanella, V., Vallès, A., Liefhebber, J. M. P., Paerels, L., Vendrell‐Tornero, C., Wattimury, H., van der Zon, T., van Rooijen, K., Golinska, M. A., Grevelink, T., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.004 · Cited by 5
Brimble, M. A., Morton, C. L., Winston, S. M., Reeves, I. L., Spence, Y., Cheng, P.-H., Zhou, J., Nathwani, A. C., Thomas, P. G., Souquette, A. H., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.188 · Cited by 7
Clinical gene technology in Australia: building on solid foundations
O’Sullivan, G. M., Philips, J. G., & Rasko, J. E. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51629 · Cited by 5
Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?
Lippi, G., & Favaloro, E. J. (2020) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000905 · Cited by 6
Gene Therapy for Hemophilia A: How Long Will It Last?
Schutgens, R. E. G. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000720 · Cited by 5
What’s next in gene therapy for Crigler-Najjar syndrome?
Aronson, S. J., Ronzitti, G., & Bosma, P. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2160237 · Cited by 5
Tracing the fate of AAV vectors in the body
Zabaleta, N., & Gil-Fariña, I. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-02047-5 · Cited by 5
CRISPR and gene editing technologies for bleeding disorders
VandenDriessche, T., Janssens, M., & Chuah, M. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251387402 · Cited by 4
Gong, J., Yang, R., Zhou, M. Q., & Chang, L. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00680-z · Cited by 5
Dai, M., Yang, N., Xu, K., Zhang, J., Li, X., Zhang, Y., & Li, W. (2023) · Cell Proliferation · doi:10.1111/cpr.13565 · Cited by 4
Consensus-Based Expert Recommendations on the Management of Hemophilia A in the Gulf Region
Alzahrani, H. A., Warsi, A., Mullah‐Ali, A., Alotaibi, G., Abu-Riash, M., Alshahrani, M. H., Siddiqui, M. A., Owaidah, T. M., & Hashmi, S. K. (2024) · Acta Haematologica · doi:10.1159/000538400 · Cited by 4
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
Minno, G. D., Spadarella, G., Calcaterra, I. L., Castaman, G., Simioni, P., CRISTOFARO, R. D., Santoro, C., Peyvandi, F., & Minno, M. N. D. D. (2024) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2024.144 · Cited by 4
Approaches and applications in transdermal and transpulmonary gene drug delivery
Zhang, A., Zhang, X., Chen, J., Shi, X., Yu, X., He, Z., Sun, J., Sun, M., & Liu, Z. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1519557 · Cited by 4
In vivo gene therapy: A strategy for mutations, degenerations, and tumors
Wang, T., Yu, M., Liu, P., Song, Z., Li, C., Yang, J., & Liu, N. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101808 · Cited by 6
mGem: AAV, from almost a virus to an awesome vector—or is it?
Srivastava, A. (2026) · mBio · doi:10.1128/mbio.02957-25 · Cited by 5
Gallo, N. B., Annand, J. W., Clarner, P., Harvey, B., Morozova, E., Ehrenfels, C., Jiang, T., Yuan, L., Kashyap, S., Lü, X., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.027 · Cited by 5
Agarwal, S., Hermans, C. R. J. R., Miesbach, W., Peyvandi, F., Sidonio, R. F., Osmond, D., Newman, V., Henshaw, J., & Pipe, S. W. (2024) · Haemophilia · doi:10.1111/hae.15025 · Cited by 4
Xie, M., Wang, L., Deng, Y., Ma, K., Yin, H., Zhang, X., Xiang, X., & Tang, J. (2024) · Journal of Ophthalmology · doi:10.1155/2024/5487973 · Cited by 4
Gene Therapy for Inherited Liver Disease: To Add or to Edit
Chen, Y., van Til, N. P., & Bosma, P. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312514 · Cited by 4
Quon, D. V. K., Wang, J., Wang, M., Pepperell, D., Park, Y. S., Kenet, G., Mahlangu, J. N., Khoo, T., Robinson, T. M., Chavele, K.-M., et al. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241304645 · Cited by 5
Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A
Zhao, M., Sun, Y., Yin, M., Zhao, J.-J., Li, S.-A., Li, G., Zhang, F., Xu, J., Meng, F., Zhang, B., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.145 · Cited by 4
Croteau, S. E. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.009 · Cited by 6
Ramamurthy, R. M., Rodriguez, M., Ainsworth, H. C., Shields, J. E., Meares, D., Bishop, C. E., Farland, A. M., Langefeld, C. D., Atala, A., Doering, C. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954984 · Cited by 4
Viral vectors engineered for gene therapy
Lundstrom, K. H. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.05.005 · Cited by 5
Adeno-associated virus–mediated transduction of PD-L1 in a rodent lung transplant model
Kahan, R., Alderete, I. S., Gao, Q., Hughes, B. A., Zhang, M., Gonzalez, T. J., Rosales, A., Carney, J., Aykun, N., Abraham, N., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.05.029 · Cited by 4
The hepatic Odyssey of Adeno-associated virus: from gene delivery to long-term outcomes
Simini, G., & Batty, P. A. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.08.028 · Cited by 3
Kashiwakura, Y., Nakajima, Y., Horinaka, K., Lopes, T. J. S., Furuta, Y., Yamaguchi, Y., Baatartsogt, N., Hayakawa, M., Katakai, Y., Uchiyama, S., et al. (2026) · Blood · doi:10.1182/blood.2025028481 · Cited by 3
Matino, D., Ligia, S., Nazy, I., Kwok, S., Moffat, K. A., Carlino, S. A., & Iorio, A. (2025) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2026.100170 · Cited by 4
Gene modification: Exploring the potential in treating kidney diseases
Ekperikpe, U. S., Zhao, S., & Daehn, I. S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108104 · Cited by 4
Susen, S., Kulkarni, R., Nogami, K., Peyvandi, F., Konkle, B. A., Santagostino, E., Khan, U., Willemze, A., Bystrická, L., Dumont, J., et al. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207251398986 · Cited by 3
Herbst, K., Pezeshkpoor, B., Klein, C., Albert, T., Lutz, P. L., Strassburg, C., Spengler, U., Goldmann, G., & Oldenburg, J. (2026) · Haemophilia · doi:10.1111/hae.70261 · Cited by 4
X-linked myotubular myopathy: an untreated treatable disease
Martín, C., & Servais, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2473430 · Cited by 3
How to Embrace Gene Therapy in Gastroenterology
Kruse, R. L., Huang, Y., & Kumbhari, V. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.01.026 · Cited by 3
Gene Therapy in Hemophilia: Latest Developments
Sanchez-Lara, P. A., Nathanson, J., & Valentino, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-93990-8_18 · Cited by 4
Advances in gene therapy for hemophilia
Kashiwakura, Y., & Ohmori, T. (2021) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.32.17 · Cited by 3
Bieńkowska, A., & Małecki, M. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3183 · Cited by 3
Failure Mode and Effects Analysis (FMEA) for Immunogenicity of Therapeutic Proteins
Chirmule, N. B., Khare, R., Khandekar, A., & Jawa, V. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.07.019 · Cited by 4
Gene-produced FVIII: measure for measure
Ragni, M. V. (2020) · Blood · doi:10.1182/blood.2020008974 · Cited by 3
Crossing the Blood-Brain Barrier with AAVs: What’s After SMA?
Chan, Y. A., & Deverman, B. E. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_21 · Cited by 3
The transcriptional landscape of human liver endothelial cells
Toledano-Sanz, P., Reventún, P., Viskadourou, M., Osburn, W. O., Alcharani, N., Lowenstein, C. J., & Arvanitis, M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008818 · Cited by 3
Imaging of Gene and Cell-Based Therapies: Basis and Clinical Trials
Jacobs, A. H., Schelhaas, S., Viel, T., Waerzeggers, Y., Winkeler, A., Zinnhardt, B., & Gelovani, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00060-0 · Cited by 5
Vithanage, T., Ratnamalala, V., Wickramaratne, K. A. C., Katulanda, G. W., & Rodrigo, C. H. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02789-1 · Cited by 3
My Pathway to Adeno-Associated Virus and Adeno-Associated Virus Gene Therapy: A Personal Perspective
Carter, B. J. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.29120.bca · Cited by 2
Low‐cost, handheld, multi‐pulse electroporators for simplified nucleic acid delivery in skin
Rohilla, P., Azizoğlu, E., Park, S., Lele, A., Prausnitz, M. R., & Bhamla, M. S. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70070 · Cited by 2
Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis
Mendes, A. C. S., Camelo, R. M., Henriques, L. C. M., de Almeida, D. L., de Jesus, V. E. A., Muniz, R. L., & Álvares-Teodoro, J. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2634281 · Cited by 2
In Cellulo Fabrication of Supramolecular Protein Assemblies
Yang, H., Song, C. W., Lu, J., & Lin, D. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c01095 · Cited by 4
Current status of hemophilia gene therapy
Kashiwakura, Y. (2024) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.35.60 · Cited by 2
Chen, Y., Li, J., Schroeder, J. A., Jing, W., & Shi, Q. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.07.023 · Cited by 2
Redosing of AAV vectors in the brain after intracranial injections: Low-ish hanging fruit?
Maguire, C. A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101469 · Cited by 2
Cellules humaines à usage thérapeutique : état de la question
Guilhot, F. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.07.051 · Cited by 3
Gene Therapy for Human Diseases: Recent Achievements and Near-Term Development Prospects
Айтбаев, К. А., Murkamilov, I. T., Абдилалимовна, М. Ж., & Yusupov, F. A. (2022) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2022-12-5-363-369 · Cited by 2
Enhancing hemophilia A gene therapy by strategic F8 deletions in AAV vectors
Zhao, J.-J., Tian, S.-N., Li, X., Peng, Z.-Y., Li, G., Zhang, F., Zhao, M., Zhang, J., & Zhang, X. (2025) · Blood Science · doi:10.1097/bs9.0000000000000217 · Cited by 4
From a bispecific monoclonal antibody to gene therapy: A new era in the treatment of hemophilia A
Mihăilă, R. G. (2022) · Biomedical Papers · doi:10.5507/bp.2022.046 · Cited by 2
Musculo-skeletal problems of the hand in haemophilia
Bravo, E., Barco, R., & Rodriguez-Merchan, E. C. (2020) · EFORT Open Reviews · doi:10.1302/2058-5241.5.190078 · Cited by 2
Emerging drugs for hemophilia A: insights into phase II and III clinical trials
Kızılocak, H., & Young, G. A. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1988073 · Cited by 4
Lifelong gene therapy in dogs with hemophilia A
Pipe, S. W. (2022) · Blood · doi:10.1182/blood.2022016359 · Cited by 2
Levien, T. L., & Baker, D. E. (2024) · Hospital Pharmacy · doi:10.1177/00185787231222506 · Cited by 1
Advanced drug delivery systems for enhancing the efficacy of RNA-based therapeutics
Alhabib, N. A., Almaniea, M. A., Alehaidib, S. M., Almansour, M. A., Aldosary, M. S., Almegbel, M. T., Alsubaie, S. A., & Alzahrani, A. M. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15029 · Cited by 1
Gene therapy for hemophilia: Recent developments and challenges (Review)
Abdulnabi, M. A., Al‐Saadi, E. A. K. D., & Al‐Bayaa, I. M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.329 · Cited by 1
Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy
Yang, Y., Chen, R., Bao, Y., Han, H., Ma, K., Pei, X., Zhang, L., & Shao, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117332 · Cited by 2
Wu, Z., Liu, H., & Wu, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-03158-6 · Cited by 1
Hurnikova, J., Venkatesan, J. K., Liu, W., Madry, H., Cucchiarini, M., & Petrovová, E. (2026) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2026.100404 · Cited by 1
Adeno-associated viral vector gene therapy for canine hemophilia
Crudele, J. M., Doshi, B. S., & Callan, M. B. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.66 · Cited by 1
Rewriting hepatic fate: emerging gene therapy strategies for liver disease
Weiskirchen, R. (2026) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2026.36 · Cited by 1
Hemophilia: a biography on therapeutical approaches
Catelli, D. H., Portich, J. P., Calvache, E. T., Weber, C. S., Hoffmann, D. S., Bosi, G. R., Sekine, L., & Silla, L. M. D. R. (2023) · Clinical & Biomedical Research · doi:10.22491/2357-9730.126437 · Cited by 1
Vishnu, P., & Aboulafia, D. M. (2025) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2025.07.010 · Cited by 2
Stimulus-Responsive Delivery Systems for Gene Therapy Products
Sakhno, N. G., & Gunar, O. V. (2025) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683825700334 · Cited by 1
Li, S., Yu, P., Wang, H., Liu, M., Wang, Q., Li, Z., Chen, S., He, C., Zhan, B. Y., Tong, L. S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.039 · Cited by 1
Using Analogue Data to Substantiate Long-Term Durability of Gene Therapies: A Narrative Review
Sharpe, M. E., Beswick, L., & Kefalas, P. (2022) · Regenerative Medicine · doi:10.2217/rme-2021-0159 · Cited by 1
Wang, Y., Hurley, A. E., Giorgi, M. D., Tanner, M. R., Hu, R.-C., Pennington, M. W., Lagor, W. R., & Beeton, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283996 · Cited by 1
Treatment progress and future prospects
Ogura, T. (2024) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.35.52 · Cited by 1
Gene Therapies in the Fight against Liver Disease: A Comprehensive Review
Leff, P., Aboona, M. B., Choday, S., Ali, Q., Wijarnpreecha, K., & Alkhouri, N. (2024) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2024/v36i55413 · Cited by 1
Platton, S., Raheja, P., Dale, C., Guy, S., Yartey, N., & Bowyer, A. E. (2024) · Haemophilia · doi:10.1111/hae.15064 · Cited by 1
Gene therapies for neurodegenerative disease: current knowledge and challenges
Arora, B., Garg, S., Shrivastav, A., Sharma, M., Sahu, B., & Kumar, U. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23826-0.00007-6 · Cited by 1
Lengler, J., Weiller, M., Horling, F., Mayrhofer, J., Schuster, M., Falkner, F. G., Gil-Fariña, I., Klugmann, M., Scheiflinger, F., Hoellriegl, W., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101424 · Cited by 2
Nonsevere hemophilia A: often overlooked, but not forgotten
Lim, M. Y., & Buckner, T. W. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000600 · Cited by 1
Lundstrom, K. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00049-4 · Cited by 1
Recent Advances in Haematology
Rahman, M. M. (2020) · Haematology Journal of Bangladesh · doi:10.37545/haematoljbd202051 · Cited by 1
Haemophilia, state of the art and new therapeutic opportunities.Preprint
Tomeo, F., Mariz, S., Brunetta, A. L., Stoyanova-Beninska, V. V., & Magrelli, A. (2020) · doi:10.22541/au.159569144.44972663 · Cited by 1
Biomarker and Bioanalytical Readouts for the Development of AAV Gene Therapy
Lu, Y., & Lembke, W. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch3 · Cited by 1
Bioanalytical Methods to Study Biodistribution and Shedding of AAV ‐Based Gene Therapy Vectors
Vettermann, C., & Soon, R. K. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch7 · Cited by 1
Haematology in the UK: A 60‐year personal perspective
Hoffbrand, A. V. (2021) · eJHaem · doi:10.1002/jha2.213
Metadata
- Authors
- Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., & Wong, W. Y.
- Affiliations
- From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy’s and St. Thomas’ NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) — all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private...
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-02
- Volume
- 382
- Issue
- 1
- Pages
- 29-40
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2998050720
- Cited by
- 448
- References
- 29
- Citations by year
- 2026: 30 · 2025: 52 · 2024: 59 · 2023: 67 · 2022: 96 · 2021: 71 · 2020: 73
- FWCI
- 48.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, adeno-associated virus gene therapy, factor VIII, long-term safety, annualized bleeding rate, transgene expression kinetics
- MeSH terms
- Dependovirus, Adult, Coagulants, Factor VIII, Follow-Up Studies, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Biomarkers, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.